Cerebral toxoplasmosis

Summary

Cerebral toxoplasmosis (MONDO:0005697) is a disease and 3 clinical trials. A subtype of toxoplasmosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebral toxoplasmosis
Mondo ID	MONDO:0005697
EFO	EFO:0007200
MeSH	D016781
DOID	DOID:10551
SNOMED CT	192701001
UMLS	C0085315
MedGen	38846
Is cancer (heuristic)	no

Also known as: Toxoplasma encephalitis

Disease family

This is a subtype of toxoplasmosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › coccidiosis › toxoplasmosis › cerebral toxoplasmosis

Related subtypes (2): congenital toxoplasmosis, ocular toxoplasmosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Atovaquone, Clarithromycin, Dexamethasone, Pyrimethamine, Sulfadiazine.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07299500	Not specified	RECRUITING	Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital
NCT00803621	Not specified	COMPLETED	Cerebral Toxoplasmosis and AIDS
NCT03226379	Not specified	COMPLETED	Driving Reduced AIDS-associated Meningo-encephalitis Mortality